Skip to main content
. 2021 Jan 20;12(1):102. doi: 10.1038/s41419-021-03393-5

Fig. 2. Therapeutic effect of neutralizing anti-KIAA1199 mAb on CIA mice.

Fig. 2

A Timeline of neutralizing anti-KIAA1199 mAb and IgG (Control) treatment in CIA mice (n = 10 per group). B Clinical scores of CIA mice treated with KIAA1199 mAb and IgG. The severity of arthritis in mice was inspected by two independent observers every 3 days in a double-blind manner and graded on a scale of 0–4 (0 = no erythema and swelling, 1 = erythema and mild swelling on tarsals or ankle joints, 2 = erythema and mild swelling from tarsals to ankles, 3 = erythema and moderate swelling from ankles to metatarsal joints, 4 = erythema and severe swelling around the ankles, feet, and digits or ankylosis of the limbs). Each paw was graded, so the maximum possible clincial score for each mouse was 16. C, D Histopathological analysis of CIA mice. Knee joints of the mice were stained by H&E and safranin O-fast green (C). Histological scores for synovial hyperplasia, inflammatory cell infiltration, and cartilage and bone erosion were shown as in D. E–H Serum levels of LMW-HA (E), IL-6 (F), IL-1β (G), and TNF-α (H) in CIA mice treated with antibodies for 4 weeks were determined by ELISA. All reactions were conducted in triplicate and data were presented with mean ± SD.